Abstract
BackgroundMonoclonal antibodies targeting the interleukin (IL)-23p19 subunit are effective in the treatment of psoriatic disease but have different molecular attributes that may translate to differences in clinical efficacy. Within this...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
